Valion Bio (VBIO) Capital Expenditures (2022 - 2025)

Valion Bio (VBIO) posted quarterly Capital Expenditures of $25000.0 for Q4 2025, up 150.0% quarter-over-quarter from $10000.0 in Q3 2025.

Valion Bio (VBIO) Capital Expenditures (2022 - 2025) Analysis & Trends

Valion Bio's Capital Expenditures history runs 3 years deep, the most recent figure standing at $25000.0 for Q4 2025.

In Q4 2025, Capital Expenditures changed N/A year-over-year to $25000.0; the TTM figure through Dec 2025 stood at $35000.0 (up 45.83% YoY), while the FY2025 annual figure was $38000.0, changed N/A from the prior year.
Capital Expenditures for Q4 2025 stood at $25000.0, up from $10000.0 in the prior quarter.
The five-year high for Capital Expenditures was $94000.0 in Q1 2023, with the low at $5000.0 in Q3 2022.
The 3-year median for Capital Expenditures is $17000.0 (2023), against an average of $27333.3.
Peak annual rise in Capital Expenditures reached 1466.67% in 2023, while the deepest fall reached 1466.67% in 2023.
Valion Bio's Capital Expenditures stood at $5000.0 in 2022, then soared by 380.0% to $24000.0 in 2023, then climbed by 4.17% to $25000.0 in 2025.
Business Quant data shows VBIO's Capital Expenditures at $25000.0 in Q4 2025, $10000.0 in Q3 2025, and $24000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Valion Bio	405,599.63	-1.79 Mn	-45,000.00	-

Download Data